NO20082566L - Kombinasjon av AZ2171 og permetrexed - Google Patents

Kombinasjon av AZ2171 og permetrexed

Info

Publication number
NO20082566L
NO20082566L NO20082566A NO20082566A NO20082566L NO 20082566 L NO20082566 L NO 20082566L NO 20082566 A NO20082566 A NO 20082566A NO 20082566 A NO20082566 A NO 20082566A NO 20082566 L NO20082566 L NO 20082566L
Authority
NO
Norway
Prior art keywords
azd2171
pemetrexed
human
combination
antiangiogenic
Prior art date
Application number
NO20082566A
Other languages
English (en)
Inventor
Stephen Robert Wedge
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0526132A external-priority patent/GB0526132D0/en
Priority claimed from GB0610708A external-priority patent/GB0610708D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20082566L publication Critical patent/NO20082566L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Ink Jet (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår en fremgangsmåte for frembringelse av en anti-angiogen og/eller vaskulær permeabilitetsreduserende effekt hos et varmblodig dyr slik som et menneske som eventuelt behandles med ioniserende stråling, særlig en fremgangsmåte for behandling av kreft, særlig kreft som involverer en fast tumor, som innbefatter administrering av AZD2171 i kombinasjon med pemetrexed; en farmasøytisk sammensetning som innbefatter AZD2171 og pemetrexed; et kombinasjonsprodukt som omfatter AZD2171 og pemetrexed for anvendelse i en fremgangsmåte for behandling av menneske- eller dyrekroppen ved behandling; et kit som innbefatter AZD2171 og pemetrexed; anvendelse av AZD2171 og pemetrexed for fremstilling av et medikament for anvendelse ved frembringelse av en anti-angiogen og/eller vaskulær permeabilitetsreduserende effekt hos et varmblodig dyr slik som et menneske som eventuelt behandles med ioniserende stråling. 1
NO20082566A 2005-12-22 2008-06-02 Kombinasjon av AZ2171 og permetrexed NO20082566L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0526132A GB0526132D0 (en) 2005-12-22 2005-12-22 Combination Therapy
GB0610708A GB0610708D0 (en) 2006-05-31 2006-05-31 Combination therapy
PCT/GB2006/004768 WO2007071970A2 (en) 2005-12-22 2006-12-19 Combination of azd2171 and pemetrexed

Publications (1)

Publication Number Publication Date
NO20082566L true NO20082566L (no) 2008-07-31

Family

ID=37964934

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082566A NO20082566L (no) 2005-12-22 2008-06-02 Kombinasjon av AZ2171 og permetrexed

Country Status (20)

Country Link
US (1) US20080306094A1 (no)
EP (1) EP1965801B1 (no)
JP (1) JP2009520787A (no)
KR (1) KR20080077678A (no)
AT (1) ATE502641T1 (no)
AU (1) AU2006328201B2 (no)
BR (1) BRPI0620118A2 (no)
CA (1) CA2631676A1 (no)
CY (1) CY1111482T1 (no)
DE (1) DE602006020919D1 (no)
DK (1) DK1965801T3 (no)
HK (1) HK1123976A1 (no)
HR (1) HRP20110365T1 (no)
IL (1) IL191797A0 (no)
NO (1) NO20082566L (no)
NZ (1) NZ568812A (no)
PL (1) PL1965801T3 (no)
PT (1) PT1965801E (no)
SI (1) SI1965801T1 (no)
WO (1) WO2007071970A2 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0406446D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
GB0406445D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
KR20060130764A (ko) * 2004-03-23 2006-12-19 아스트라제네카 아베 병용 요법
CA2614002A1 (en) * 2005-07-06 2007-01-11 Astrazeneca Ab Combination therapy of cancer with azd2171 and gemcitabine
BRPI0620140A2 (pt) * 2005-12-22 2011-11-01 Astrazeneca Ab uso de zd6474 ou de um sal farmaceuticamente aceitável do mesmo e pemetrexed, composição farmacêutica, kit, e, método para a produção de um efeito antiangiogênico e/ou redutor da permeabilidade vascular
US20090221615A1 (en) * 2008-02-29 2009-09-03 Guru Reddy Combination anti-cancer agents
KR20130055562A (ko) 2010-03-08 2013-05-28 스펙트럼 파마슈티컬즈 인크 암을 치료하기 위한 티옥산톤계 자가포식작용 저해제 치료제
WO2017020048A1 (en) * 2015-07-30 2017-02-02 Expression Pathology, Inc. QUANTIFYING FR-α AND GART PROTEINS FOR OPTIMAL CANCER THERAPY

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1087785A2 (en) * 1998-06-15 2001-04-04 Arch Development Corporation Combination of radiotherapy and anti-angiogenic factors
KR100838617B1 (ko) * 1999-02-10 2008-06-16 아스트라제네카 아베 혈관형성 억제제로서의 퀴나졸린 유도체
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
GB0316123D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
GB0316127D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
GB0330002D0 (en) * 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
GB0406445D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
KR20060130764A (ko) * 2004-03-23 2006-12-19 아스트라제네카 아베 병용 요법
GB0406446D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
EP1761281A1 (en) * 2004-06-04 2007-03-14 Pfizer Products Incorporated Method for treating abnormal cell growth
WO2006035203A1 (en) * 2004-09-27 2006-04-06 Astrazeneca Ab Cancer combination therapy comprising azd2171 and imatinib
CA2614002A1 (en) * 2005-07-06 2007-01-11 Astrazeneca Ab Combination therapy of cancer with azd2171 and gemcitabine
CN101370519B (zh) * 2005-12-15 2013-07-24 阿斯利康(瑞典)有限公司 治疗癌症的促血管生成素-2拮抗剂和VEGF-A、KDR和/或Flt1拮抗剂的组合
BRPI0620140A2 (pt) * 2005-12-22 2011-11-01 Astrazeneca Ab uso de zd6474 ou de um sal farmaceuticamente aceitável do mesmo e pemetrexed, composição farmacêutica, kit, e, método para a produção de um efeito antiangiogênico e/ou redutor da permeabilidade vascular

Also Published As

Publication number Publication date
BRPI0620118A2 (pt) 2011-11-01
ATE502641T1 (de) 2011-04-15
US20080306094A1 (en) 2008-12-11
WO2007071970A3 (en) 2007-08-09
CY1111482T1 (el) 2015-08-05
HK1123976A1 (en) 2009-07-03
WO2007071970A2 (en) 2007-06-28
AU2006328201A1 (en) 2007-06-28
DK1965801T3 (da) 2011-06-14
HRP20110365T1 (hr) 2011-06-30
PT1965801E (pt) 2011-05-25
PL1965801T3 (pl) 2011-07-29
DE602006020919D1 (de) 2011-05-05
SI1965801T1 (sl) 2011-06-30
KR20080077678A (ko) 2008-08-25
CA2631676A1 (en) 2007-06-28
NZ568812A (en) 2011-09-30
EP1965801A2 (en) 2008-09-10
IL191797A0 (en) 2008-12-29
EP1965801B1 (en) 2011-03-23
JP2009520787A (ja) 2009-05-28
AU2006328201B2 (en) 2010-08-19

Similar Documents

Publication Publication Date Title
NO20082567L (no) Kombinasjon av ZD6474 og pemetrexed
MX2007003505A (es) Combinacion que comprende zd6474 e imatinib.
CY1111482T1 (el) Συνδυασμος azd2171 και πεμετρεξεδης
HRP20080597T3 (en) Cancer combination therapy comprising azd2171 and zd1839
NO20064755L (no) Kombinasjonsterapi
NO20056171L (no) Kombinasjonsterapi
WO2005092384A3 (en) Combination therapy with azd2171 and a platinum anti-tumour agent
NO20064754L (no) Kombinasjonsterapi
WO2007003933A3 (en) Combination therapy of cancer with azd2171 and gemcitabine

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application